Another Phase I study is exploring the safety and activity of ASTX727, a novel agent that combines decitabine with a cytidine deaminase inhibitor cedazuridine in recurrent/progressive non-enhancing IDH-mut gliomas (NCT03922555) (Table 3). The gene discussed is IDH2; the disease is central nervous system cancer.